Wanbury Limited (WANBURY) AI Stock Analysis

• Market Cap: ₹8.24B
• Dividend Yield: N/A
• Average Volume (3M): 5.90K
• Price to Earnings (P/E): 19.1
• Beta (1Y): 2.16
• Revenue Growth: 12.37%
• EPS Growth: -17.98%
• Country: IN
• Employees: 1,491
• Sector: Healthcare
• Sector Strength: 41
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 4.10
• Shares Outstanding: 32,877,000
• 10 Day Avg. Volume: 6,729
• 30 Day Avg. Volume: 5,899
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ₹274.00
• Price Target Upside: 9.19% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 63 Neutral
• Price Target: ₹274.00 ▲(9.19% Upside)

Wanbury Limited's stock score is primarily influenced by its strong financial performance, despite high leverage and negative free cash flow. Technical indicators suggest bearish momentum, while the valuation appears reasonable. The absence of earnings call data and corporate events limits additional insights.

Wanbury Limited Business Overview & Revenue Model

Company Description

Wanbury Limited is an Indian pharmaceutical company engaged in the manufacturing and marketing of a wide range of pharmaceutical formulations and bulk drugs. With a focus on the domestic and international markets, Wanbury specializes in active pharmaceutical ingredients (APIs) and formulations across therapeutic segments like pain management, gynecology, and anti-diabetic medications.

How the Company Makes Money

Wanbury Limited generates revenue primarily through the sale of its pharmaceutical formulations and active pharmaceutical ingredients (APIs). The company serves both domestic and international markets, offering its products to various healthcare providers, hospitals, and pharmacies. A significant portion of its income is derived from its robust export business, where it supplies APIs and finished formulations to other pharmaceutical companies worldwide. Additionally, strategic partnerships and collaborations with global pharmaceutical firms enhance its revenue streams, allowing it to expand its market reach and leverage its manufacturing capabilities efficiently.

Wanbury Limited Financial Statement Overview

Summary

Wanbury Limited demonstrates strong revenue growth and improving profitability margins. However, challenges include high leverage and consistent free cash flow deficits, which could pose risks to financial stability.

Income Statement

Wanbury Limited shows a strong recovery in revenue with a noticeable growth rate from 2023 to 2025. The gross profit and EBIT margins have improved, indicating enhanced operational efficiency. However, net profit margin is fluctuating, showing some instability in profitability. Despite this, the overall trend appears positive with EBITDA margins also showing strength.

Balance Sheet

The company's debt-to-equity ratio indicates high leverage which poses a potential risk, but the positive stockholders' equity in 2025 is a significant improvement from previous negative values. The equity ratio is low, indicating a higher reliance on debt, but the return on equity is improving, suggesting better profitability management.

Cash Flow

Operating cash flow has shown improvement with positive trends, though free cash flow remains negative in recent years, highlighting potential liquidity challenges. The operating cash flow to net income ratio is strong, indicating efficient cash management relative to earnings.

Breakdown	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	6.00B	5.74B	4.98B	5.07B	3.87B
Gross Profit	3.05B	2.65B	1.89B	2.00B	1.61B
EBITDA	798.13M	985.49M	234.91M	1.13B	204.23M
Net Income	305.30M	559.56M	-103.96M	814.74M	-126.06M
Balance Sheet
Total Assets	4.14B	3.43B	3.04B	3.53B	2.89B
Cash, Cash Equivalents and Short-Term Investments	150.63M	34.00M	48.04M	226.56M	101.31M
Total Debt	1.77B	1.16B	1.09B	1.08B	2.04B
Total Liabilities	3.55B	3.16B	3.36B	3.76B	4.45B
Stockholders Equity	592.72M	279.41M	-61.54M	-234.20M	-1.56B
Cash Flow
Free Cash Flow	-229.26M	-134.45M	71.69M	308.65M	122.53M
Operating Cash Flow	261.02M	39.78M	197.97M	405.23M	166.81M
Investing Cash Flow	-511.74M	-166.25M	-88.38M	5.87M	80.44M
Financing Cash Flow	257.33M	145.53M	-319.91M	-285.85M	-173.85M

Wanbury Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 250.95
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:WANBURY, the sentiment is Negative. The current price of 250.95 is below the 20-day moving average (MA) of 262.22, below the 50-day MA of 276.28, and below the 200-day MA of 253.81, indicating a neutral trend. The MACD of -4.12 indicates Negative momentum. The RSI at 42.13 is Neutral, neither overbought nor oversold. The STOCH value of 40.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:WANBURY.

Wanbury Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SAKAR	68 Neutral	₹7.26B	36.27		―	21.65%	73.84%
KILITCH	65 Neutral	₹7.87B	27.53		―	28.47%	78.96%
WANBURY	63 Neutral	₹8.24B	19.08		―	12.37%	-17.98%
KOPRAN	57 Neutral	₹7.72B	22.08		1.87%	-1.83%	-41.11%
THEMISMED	56 Neutral	₹9.78B	33.15		0.45%	-6.86%	-118.14%
Sector *	51 Neutral	$7.43B	-0.36	-45.45%	2.27%	22.98%	-2.34%

Wanbury Limited Corporate Events

Wanbury Limited Announces Key Appointments and Strategic Decisions

Wanbury Limited announced the appointment of Mr. Chandran Krishnamoorthy as a Whole Time Director, effective August 4, 2025. The company also approved its unaudited financial results for the first quarter ending June 30, 2025, and granted 91,500 stock options to employees. Additionally, the company initiated the closure of three foreign subsidiaries, which had not commenced operations, ensuring no impact on its revenue or business.

Wanbury Limited Announces Key Board Decisions and Subsidiary Closures

Wanbury Limited announced several key decisions following its Board of Directors meeting on August 4, 2025. The company approved its unaudited financial results for the first quarter ending June 30, 2025, and granted 91,500 stock options to employees under its Employee Stock Option Plan 2016. Additionally, the reappointment of Mr. Chandran Krishnamurthy as a Whole-time Director for a five-year term was approved, pending shareholder approval. Furthermore, Wanbury Limited initiated the closure of three foreign subsidiaries, which had not commenced operations, ensuring no impact on the company’s revenue or business.